TScan Therapeutics, Inc. (TCRX) Tops Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts TCRX Hot Sheet
Join SI Premium – FREE
TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q2 EPS of ($0.28), $0.05 better than the analyst estimate of ($0.33).
For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rockstar Energy founder seeks CEO role at Celsius Holdings
- Evommune, Inc. (EVMN) Misses Q2 EPS by 20c
- SpyGlass Pharma (SGP) Reports Q2 Loss of $0.59
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
